Skip to main content

Vaccines for the 21st Century A Tool for Decisionmaking (2000) / Chapter Skim
Currently Skimming:

Appendix 10: Histoplasma capsulatum
Pages 207-212

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 207...
... DISEASE BURDEN Epidemiology For the purposes of the calculations in this report, the committee estimated that there are 500,000 new infections with Histoplasma capsulatum each year in the United States. The incidence rate varies with age; the highest incidence is seen in people between 15 and 34 years of age.
Read the entire page →
From page 208...
... Disseminated histoplasma was associated with an acute and severe phase of illness followed by a more moderate but lengthy recovery. Health utility indexes associated with histoplasma disease range from .9 for a mild flu-like illness to .39 for the acute illness associated with disseminated disease.
Read the entire page →
From page 209...
... Approximately 40% of patients with chronic pulmonary disease would require hospitalization and all of the patients would require outpatient treatment similar to that estimated for disseminated disease but for 3 times the duration and cost. VACCINE DEVELOPMENT The committee assumed that it will take 15 years until licensure of a histoplasma vaccine and that $360 million needs to be invested.
Read the entire page →
From page 210...
... Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $860,000. If a vaccine program for H
Read the entire page →
From page 211...
... 100% $sO 2.0 $150 1.0 $350 1.0 Pneumonitis: w/ inpatient inpatient care 100% $5,000 1.0 outpatient care 100% $350 1.0 Disseminated histoplasmosis disseminated intravasc ular coagulation, sple nomegaly, hepatomegaly, fever outpatient only 50% $1,250 1.0 so% $s,ooo 1.0 recovery Chronic pulmonary symptomatic (untreat ed, initial treatment) outpatient treatment 100% $1,250 3.0 50% $1,250 1.0 40% $s,ooo 1.0 .
Read the entire page →
From page 212...
... Advance Report of Final Natality Statistics, 1994. Monthly Vital Statistics Report 1996; 44.
Read the entire page →

Key Terms

  • outpatient treatment
  • target population
  • disseminated disease
  • committee assumptions
  • using committee

  • including time
  • care costs
  • monetary costs
  • require outpatient
  • chronic pulmonary

  • qalys gained
  • qaly gained
  • illness associated
  • committee estimated
  • costs saved

  • vaccine development
  • program cost
  • summarizes vaccine
  • vaccines considered
  • require hospitalization

  • histoplasma capsulatum
  • histoplasma disease
  • disease scenarios
  • pulmonary disease
  • average age

  • current population
  • statistics report
  • river valley
  • natality statistics
  • population reports


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.